NRx: Phase 2b/3 Trial Shows Clinically Significant Relief from Respiratory Distress in Critical COVID-19

- NRx Has Provided Updated Data to US Food and Drug Administration (FDA) in Support of Emergency Use Authorization Request for ZYESAMI™ (aviptadil)

- NRx to Submit Breakthrough Therapy Designation to FDA for ZYESAMI™ for the Treatment of Respiratory Failure in Patients with Critical COVID-19

https://finance.yahoo.com/news/nrx-pharmaceuticals-announces-finding-zyesami-120600828.html